Long-term survival analysis in combined transarterial embolization and stereotactic body radiation therapy versus stereotactic body radiation monotherapy for unresectable hepatocellular carcinoma >5 cm
Open Access
- 3 November 2016
- journal article
- research article
- Published by Springer Science and Business Media LLC in BMC Cancer
- Vol. 16 (1), 1-9
- https://doi.org/10.1186/s12885-016-2894-9
Abstract
The survival following transarterial chemoembolization (TACE) alone is still low in unresectable hepatocellular carcinoma (HCC) with almost patients developing disease progression after treatment. There is need to investigate additional therapeutic options that would intensify the initial response to TACE. The present study was to retrospectively compare the outcome and evaluate the prognostic factors of stereotactic body radiation therapy (SBRT) alone or as an adjunct to transarterial embolization (TAE) or TACE in the treatment of HCC >5 cm. From January 2011 to April 2015, 77 patients received SBRT followed by TAE or TACE (TAE/TACE + SBRT group) and 50 patients received SBRT alone (SBRT group). The dose of SBRT was 30–50 Gy which was prescribed in 3–5 fractions. Eligibility criteria were: a longest tumor diameter >5.0 cm and Child-Turcotte-Pugh (CTP) Class A or B. Exclusion criteria included tumor thrombus, lymph node involvement and extrahepatic metastasis. The median follow-up period was 20.5 months. Median tumor size was 8.5 cm (range, 5.1–21.0 cm). Median overall survival (OS) in the TAE/TACE + SBRT group was 42.0 months versus 21.0 months in the SBRT group. The 1-, 3- and 5-year OS was 75.5, 50.8, and 46.9 % in the TAE/TACE + SBRT group and was 62.4, 32.9, and 32.9 % in the SBRT group, respectively (P = 0.047). The 1-, 3- and 5-year distant metastasis-free survival (DMFS) was 66.3, 44.3, and 40.6 % in the TAE/TACE + SBRT group and was 56.8, 26.1, and 17.4 % in the SBRT group, respectively (P = 0.049). The progression-free survival (PFS) and local relapse-free survival (LRFS) were not significantly different between the two groups. In the entire patient population, a biologically effective dose (BED10) ≥100 Gy and an equivalent dose in 2 Gy fractions (EQD2) ≥74 Gy were significant prognostic factors for OS, PFS, LRFS and DMFS. SBRT combined with TAE/TACE may be an effective complementary treatment approach for HCC >5 cm in diameter. BED10 ≥100 Gy and EQD2 ≥74 Gy should receive more attention when the SBRT plan is designed.Keywords
Funding Information
- the Scientific Research Foundation of Guangxi Traditional Chinese Medical University, China (RKZ201009, P2010069)
This publication has 28 references indexed in Scilit:
- Global cancer statistics, 2012CA: A Cancer Journal for Clinicians, 2015
- Sequential Phase I and II Trials of Stereotactic Body Radiotherapy for Locally Advanced Hepatocellular CarcinomaJournal of Clinical Oncology, 2013
- EASL–EORTC Clinical Practice Guidelines: Management of hepatocellular carcinomaJournal of Hepatology, 2012
- Phase I feasibility trial of stereotactic body radiation therapy for primary hepatocellular carcinomaClinical and Translational Oncology, 2010
- Multi-Institutional Phase I/II Trial of Stereotactic Body Radiation Therapy for Liver MetastasesJournal of Clinical Oncology, 2009
- Stereotactic body radiation therapy for primary and metastatic liver tumors: A single institution phase i-ii studyActa Oncologica, 2006
- A phase I trial of stereotactic body radiation therapy (SBRT) for liver metastasesInternational Journal of Radiation Oncology*Biology*Physics, 2005
- Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trialThe Lancet, 2002
- Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinomaJournal of Hepatology, 2002
- Hepatic toxicity resulting from cancer treatmentInternational Journal of Radiation Oncology*Biology*Physics, 1995